Dr. Stuart Titus Clarifies Medical Cannabis Policy in Letter to Brazilians
Ryan Allway
August 22nd, 2016
News, Top Story
Medical Marijuana Inc. (OTC: MJNA) has successfully achieved licenses to import its RSHO™ cannabidiol (“CBD”) oil into numerous Latin American countries, but many would-be consumers still don’t fully understand how the product differs from marijuana. In an open letter, CEO Dr. Stuart Titus attempted to eliminate the confusion surrounding hemp-derived CBD – including its own RSHO™ product line – and explain its potential benefits.
In this article, we will take a closer look at the letter to Brazilians and what the sentiments mean for Brazil and Latin America moving forward.
Open Letter to Brazilians
Dr. Titus began by explaining that, although hemp and marijuana belong to the same plant family (cannabis, or technically Cannabis L Sativa), the two plants are extremely different.
Marijuana contains large amounts of psychoactive tetrahydrocannabinol (“THC”), while hemp contains relatively large amounts of non-psychoactive CBD (Cannabidoil). Dr. Titus describes these differences and cites pictures in his presentation to assist individuals in distinguishing the “offspring” of the cannabis parent: marijuana vs hemp.
One can find a link to Dr. Titus’ By-Lined Presentation here: http://www.boavidaonline.com.br/uso-da-maconha-medicinal-com-o-p-h-d-stuart-titus/
According to the US Government patent # 6,630,507 regarding the therapeutic usage of cannabinoids, titled: Cannabinoids as Antioxidants and Neuroprotectants – the research team, including Nobel Prize Winning Laureate, Dr. Julius Axelrod concluded that:
“Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses…”
Thus, in many indications, it’s CBD that holds the most therapeutic value among cannabinoids rather than the psychoactive THC that gives users a ‘high”.
In April 2014, Brazil authorized the import of cannabidiol for a child suffering from CDKL5 epilepsy, which can cause more than 80 seizures per day and is usually fatal. Named for a defective gene, (technically the CDKL5 gene), many patients suffering from seizures have found that CBD can reduce or eliminate these incidents and dramatically improve their family’s quality of life. Without government support, many families are forced to resort to illegal and potentially dangerous methods of importation of the botanical hemp-based CBD.
Dr. Titus concluded by saying that the first battle to import CBD oil in Brazil has been won as of April 2014, but the war on cannabinoids across Latin America is not over. While the scientific basis has been proven, the subject is still controversial and little discussed in the country. He urged people to start raising awareness among the general public and support families that have opted to import the therapy via doctor prescription to treat a growing number of serious medical indications.
Progress in Latin America
Medical Marijuana Inc. has made tremendous progress bringing RSHO™ across Latin America with import licenses in Brazil, Mexico, Paraguay, and other countries, including 12 product registrations within Puerto Rico. With the legalization of recreational and medical marijuana in Canada and the U.S., many Latin American countries have followed suit with Uruguay becoming the first country in the world to fully legalize and regulate recreational marijuana for all of its citizens.
The company’s RSHO™ – short for Real Scientific Hemp Oil™ – has been a pioneer in securing these import licenses. With this early advantage, the company is positioning itself as both a thought leader and a leading brand across many potentially large end markets. Mexico’s market alone is comparable in size to California’s market in the United States, which has already generated billions of dollars in medical marijuana sales.
In Mexico, the Company has had to develop a special form of botanical CBD, known as RSHO-X.
This is a fully THC-free version of MJNAs flagship product, RSHO and was accepted by the Mexico regulatory authority COFEPRIS as of Feb 1 2016 for import via Doctor Prescription. There are many families who now import and even more “in the pipeline” waiting to get approval for their import by Mexico customs officials. As of today, Medical Marijuana Inc.’s
RSHO-X remains the only LEGAL cannabis-based product allowed into Mexico.
Further, RSHO-X is the ONLY cannabis based product that qualifies for World Anti-Doping Standards – a huge accomplishment in light of the 2016 Summer Olympics in Rio de Janeiro, Brazil. This opens a world of new potential users from professional sport and Olympic athletes to US Military personnel and others who are regularly drug-screened.
Medical Marijuana Inc. (OTC: MJNA) plans to continue these efforts as it expands its footprint in existing countries and looks to move into new countries. With growing support among politicians, the company is rapidly building a brand identity in one of the fastest growing regions of the world. Paraguay recently (as of May 15 2016) allowed RSHO into the country for a petitioning family with a child with epilepsy. The Lain American domino effect is in full force.
More Regarding Dr. Titus’ By-Lined Article
In the article, Dr. Titus further describes many concepts important to the overall cannabis and CBD industries, such as The Entourage Effect, Clinical EndoCannabinoid Deficiency Syndrome and touches on some of the world-wide cannabinoid research into a few of the indications being studied:
Osteoporosis: https://www.sciencedaily.com/releases/2015/07/150716124359.htm
Accelerated Bone Healing – {same link as above}
Depression: http://www.ncbi.nlm.nih.gov/pubmed/26711860
Traumatic Brain Injury: https://www.kannalife.com/kannalife-sciences-inc-signs-new-license-agreement-with-national-institutes-of-health-nih-for-treatment-of-chronic-traumatic-encephalopathy/
Alzheimer’s: https://www.salk.edu/news-release/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells/
Pain and Muscular Spasticity in Multiple Sclerosis: https://globenewswire.com/news-release/2016/01/05/799642/0/en/AXIM-Featured-by-Reuters-Biotech-Receives-Cannabis-Strains-at-Discount-for-Gum-to-Treat-Multiple-Sclerosis.html
Cancer: http://mct.aacrjournals.org/content/6/11/2921 and http://molpharm.aspetjournals.org/content/70/3/897.full
Looking Ahead
Medical Marijuana Inc. (OTC: MJNA) has become an early pioneer in bringing hemp-based CBD therapies to Latin American end markets. In an open letter to Brazilians, the company encouraged citizens to understand the differences between medical marijuana and hemp-based CBDs and be vocal in supporting the many potential benefits of non-psychoactive CBDs in order to bring much-needed relief to more families. Interested parties should keep an eye on developments throughout Latin America as the company strives to open more doors to those in need of relief.
For more information, visit the company’s website at http://www.medicalmarijuanainc.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
CannaTrac® is dedicated to bringing safety to the cannabis industry by serving as the industry’s leading cashless mobile payment system solution. CannaTrac® created the CannaCard® and the CannaCard App™ to provide consumers and retailers with a convenient way to benefit from increased safety and convenience through cashless purchases within the legal cannabis industry.
Segra is a plant micropropagation (also known as “tissue culture”) company specializing in cannabis. Segra is focused on producing standardized cannabis plantlets on an industrial scale to meet global demand for clean, disease-free starting materials. The Company is currently developing cannabis micropropagation nurseries to serve large-scale producers in Canada and the US (California). In Canada, […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
